We advised the underwriters on the offering

Davis Polk advised the representative of the several underwriters in connection with an SEC-registered follow-on offering by Olema Pharmaceuticals, Inc. of 11,500,000 shares of common stock, which included 1,500,000 shares of common stock from the full exercise of the underwriters’ option to purchase additional shares. The offering resulted in gross proceeds of $218.5 million for Olema. Olema’s common stock is listed on the Nasdaq Global Select Market under the symbol “OLMA.”

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. The company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance. It is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Paula Gergen and Jared Madnick. Partner David R. Bauer and associates Shreya R. Kundur and Bari Britvan provided intellectual property advice. Partner Michael Mollerus and associate Hunter P. Shaw provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post